NASDAQ:TRIL - Trillium Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.25
  • Forecasted Upside: 95.85 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.85
▼ -0.84 (-7.19%)
1 month | 3 months | 12 months
Get New Trillium Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRIL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$21.25
▲ +95.85% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Trillium Therapeutics in the last 3 months. The average price target is $21.25, with a high forecast of $28.00 and a low forecast of $14.00. The average price target represents a 95.85% upside from the last price of $10.85.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Trillium Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2020Bloom BurtonDowngradeBuy ➝ AccumulateHigh
i
Rating by D. Martin at Bloom Burton
11/18/2020Craig HallumBoost Price Target$15.00 ➝ $21.00High
i
11/18/2020HC WainwrightBoost Price TargetBuy$16.50 ➝ $22.00High
i
Rating by S. Ramakanth at HC Wainwright
10/12/2020Evercore ISIInitiated CoverageOutperform$28.00High
i
10/5/2020HC WainwrightReiterated RatingHoldHigh
i
Rating by S. Ramakanth at HC Wainwright
9/10/2020HC WainwrightUpgradeNeutral ➝ Buy$16.50High
i
Rating by S. Ramakanth at HC Wainwright
9/9/2020JMP SecuritiesBoost Price TargetPositive ➝ Market Outperform$10.00 ➝ $14.00High
i
Rating by Reni Benjamin at JMP Securities
8/17/2020Craig HallumInitiated CoverageBuy$15.00High
i
8/13/2020HC WainwrightReiterated RatingHoldHigh
i
5/26/2020JMP SecuritiesInitiated CoverageOutperform$10.00High
i
1/7/2020CowenReiterated RatingBuyMedium
i
11/18/2019HC WainwrightReiterated RatingHoldHigh
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/19/2019HC WainwrightDowngradeBuy ➝ NeutralLow
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/15/2019CowenReiterated RatingBuyMedium
i
5/17/2019HC WainwrightSet Price TargetBuy$4.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/13/2019HC WainwrightLower Price TargetBuy$10.00 ➝ $4.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/20/2018CowenReiterated RatingBuyLow
i
Rating by Boris Peaker at Cowen Inc
11/15/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/13/2018HC WainwrightReiterated RatingBuy$10.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/17/2018HC WainwrightSet Price TargetBuy$10.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/13/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$7.00Low
i
Rating by J. Chang at SVB Leerink LLC
3/12/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/14/2017HC WainwrightReiterated RatingBuy$10.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/14/2017HC WainwrightSet Price TargetBuy$7.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/17/2017HC WainwrightInitiated CoverageBuy ➝ Buy$7.00High
i
Rating by S. Ramakanth at HC Wainwright
7/5/2017CowenReiterated RatingBuyMedium
i
Rating by Boris Peaker at Cowen Inc
6/9/2017LADENBURG THALM/SH SHReiterated RatingBuy$18.00Low
i
12/5/2016CowenReiterated RatingBuyN/A
i
Rating by Boris Peaker at Cowen Inc
11/4/2016Bloom BurtonReiterated RatingBuyN/A
i
Rating by D. Martin at Bloom Burton
11/3/2016SVB LeerinkReiterated RatingOutperform$20.00N/A
i
11/3/2016CowenReiterated RatingBuyN/A
i
Rating by Boris Peaker at Cowen Inc
10/6/2016BTIG ResearchInitiated CoverageBuy$21.00N/A
i
8/15/2016SVB LeerinkReiterated RatingOutperform$20.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
8/3/2016LADENBURG THALM/SH SHInitiated CoverageBuy$18.00N/A
i
6/12/2016CowenReiterated RatingBuyN/A
i
Rating by Boris Peaker at Cowen Inc
6/6/2016OppenheimerReiterated RatingBuy$38.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
6/6/2016CowenReiterated RatingBuyN/A
i
Rating by Boris Peaker at Cowen Inc
5/19/2016OppenheimerReiterated RatingOutperform$32.00N/A
i
5/16/2016SVB LeerinkReiterated RatingOutperform$20.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
5/14/2016CowenReiterated RatingBuyN/A
i
Rating by Boris Peaker at Cowen Inc
3/17/2016SVB LeerinkReiterated RatingOutperform$20.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
3/11/2016SVB LeerinkReiterated RatingOutperform$29.00 ➝ $20.00N/A
i
(Data available from 3/2/2016 forward)
Trillium Therapeutics logo
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $10.85
$10.82
$11.94

50 Day Range

MA: $13.19
$11.35
$14.97

52 Week Range

Now: $10.85
$2.50
$20.96

Volume

51,046 shs

Average Volume

1,434,796 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Trillium Therapeutics?

The following Wall Street research analysts have issued reports on Trillium Therapeutics in the last twelve months: Bloom Burton, Craig Hallum, Evercore ISI, HC Wainwright, JMP Securities, and Zacks Investment Research.
View the latest analyst ratings for TRIL.

What is the current price target for Trillium Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Trillium Therapeutics in the last year. Their average twelve-month price target is $21.25, suggesting a possible upside of 78.9%. Evercore ISI has the highest price target set, predicting TRIL will reach $28.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $14.00 for Trillium Therapeutics in the next year.
View the latest price targets for TRIL.

What is the current consensus analyst rating for Trillium Therapeutics?

Trillium Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TRIL will outperform the market and that investors should add to their positions of Trillium Therapeutics.
View the latest ratings for TRIL.

What other companies compete with Trillium Therapeutics?

How do I contact Trillium Therapeutics' investor relations team?

Trillium Therapeutics' physical mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company's listed phone number is 416-595-0627 and its investor relations email address is [email protected] The official website for Trillium Therapeutics is www.trilliumtherapeutics.com.